Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials